ALTEOGEN Inc. (KOSDAQ:196170)

South Korea flag South Korea · Delayed Price · Currency is KRW
366,500
-13,500 (-3.55%)
Apr 16, 2025, 3:30 PM KST
113.95%
Market Cap 20.25T
Revenue (ttm) 102.85B
Net Income (ttm) 62.25B
Shares Out 53.30M
EPS (ttm) 1,163.00
PE Ratio 325.32
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 313,528
Average Volume 571,399
Open 376,500
Previous Close 380,000
Day's Range 366,000 - 379,000
52-Week Range 158,900 - 459,500
Beta 1.34
RSI 48.76
Earnings Date May 15, 2025

About ALTEOGEN

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 145
Stock Exchange KOSDAQ
Ticker Symbol 196170
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.